Database screening for pathogenic sequences

Introduction

Database screening for pathogenic sequences refers to the systematic examination of DNA and RNA sequences against biological databases to identify genetic material associated with disease-causing organisms, toxins, or potentially harmful biological activities. It is an important part of biosecurity, biotechnology research, synthetic biology, pharmaceutical development, and public health protection.

Researchers and biotechnology companies use sequence databases to identify genetic similarities, classify microorganisms, study infectious diseases, and assess biological risks. Screening may also be used by organisations that synthesise DNA to identify potentially hazardous sequence requests before providing synthetic genetic material.

However, access to genetic databases and sequence information creates legal and ethical concerns. These include privacy, scientific freedom, intellectual property, cybersecurity, responsible research, and the prevention of misuse of biological information.

Legal framework governing database screening

India does not currently have one comprehensive statute exclusively regulating database screening for pathogenic sequences. Instead, several existing legal frameworks may apply.

1. Environment (Protection) Act, 1986

The Act provides powers to regulate activities that may create environmental and biological risks. It forms the foundation for several rules governing genetically modified organisms and hazardous microorganisms.

2. Rules, 1989 under the Environment (Protection) Act

The Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms/Genetically Engineered Organisms or Cells Rules, 1989 establish regulatory controls over specified activities involving hazardous microorganisms and genetically engineered organisms.

These Rules are relevant to institutional biosafety, handling, import, export, and other regulated activities involving potentially hazardous biological materials.

3. Information Technology Act, 2000

The Act addresses unauthorised access, misuse of computer resources, and certain forms of cybercrime. It may apply where pathogenic sequence databases are accessed, modified, or disclosed unlawfully.

4. Digital Personal Data Protection Act, 2023

The Act may apply when sequence databases contain digital personal data, such as identifiable human genetic information. Its provisions operate subject to applicable commencement requirements and rules.

5. Biological Diversity Act, 2002

The Act regulates access to biological resources and associated traditional knowledge within its scope. It may become relevant when sequence information is connected to biological resources obtained from India.

Internationally, important frameworks include:

Biological Weapons Convention, 1972: Prohibits the development, production, acquisition, and stockpiling of biological and toxin weapons.

Convention on Biological Diversity, 1992: Addresses biodiversity conservation and sustainable use.

Nagoya Protocol, 2010: Establishes an international framework for access to genetic resources and benefit-sharing.

WHO Global Guidance Framework for the Responsible Use of the Life Sciences: Encourages responsible research governance and measures against biological misuse.

Importance of screening pathogenic sequences

Pathogenic sequence screening helps identify biological risks before genetic material is synthesised, transferred, or used in research. It can support responsible scientific development while reducing opportunities for unauthorised access to potentially dangerous biological information.

For example, a DNA synthesis company may assess an incoming sequence order against recognised reference databases and review whether the request raises legitimate biosecurity concerns. Similarly, a research institution may use sequence databases to classify genetic material and evaluate whether additional biosafety review is required.

Important objectives include:

Biosecurity: Identifying potentially concerning biological sequence requests.

Public health: Supporting the identification and surveillance of disease-causing organisms.

Research integrity: Improving the reliability of biological sequence classification.

Regulatory compliance: Helping institutions meet applicable biosafety requirements.

Responsible innovation: Supporting scientific research while considering potential misuse.

Legal and technical requirements for database screening

An effective screening framework should establish clear institutional responsibilities and reliable governance procedures.

1. Database accuracy: Screening systems should rely on scientifically validated reference information and regularly updated records.

2. Responsible access: Access to sensitive sequence databases should be limited to authorised users with legitimate research or regulatory purposes.

3. Screening accountability: Organisations should maintain records showing that appropriate screening assessments were conducted.

4. Human genetic privacy: Where databases contain identifiable human genetic information, applicable consent and data protection requirements must be respected.

5. Independent review: Uncertain or potentially concerning screening results should be reviewed by qualified scientific and biosafety professionals.

6. Information security: Institutions should protect sequence databases against unauthorised access, alteration, and disclosure.

Important case laws

Direct Indian judicial decisions specifically concerning database screening for pathogenic sequences are limited. However, the following cases establish legal principles relevant to biological safety, scientific information, privacy, and biotechnology regulation.

1. K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21. The judgment established that the collection and processing of personal information must satisfy legality, legitimate purpose, and proportionality.

This decision is relevant where sequence databases contain identifiable human genetic information. Screening and sharing such information must respect individual privacy and applicable data protection requirements.

2. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999)

The Supreme Court examined the importance of scientific expertise in environmental decision-making. It emphasised that environmental disputes involving complex scientific questions require reliable technical knowledge and informed evaluation.

The judgment is relevant by analogy because pathogenic sequence screening involves specialised scientific assessments. Regulatory authorities should rely on qualified experts and scientifically credible information when evaluating biological risks.

3. Vellore Citizens' Welfare Forum v. Union of India (1996)

The Supreme Court recognised the precautionary principle as an essential part of Indian environmental law. The judgment established that environmental protection should not be postponed merely because scientific certainty is incomplete.

This principle is relevant to biological risk assessment because potentially serious biological hazards may require precautionary regulatory attention even where all scientific uncertainties have not been resolved.

4. Novartis AG v. Union of India (2013)

The Supreme Court examined pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. It emphasised the importance of demonstrating genuine therapeutic advancement in certain pharmaceutical inventions.

Although the case did not concern pathogenic sequence screening, it is relevant to biotechnology research because genetic information and biological discoveries may raise questions concerning patent protection, scientific evidence, and access to innovation.

Challenges in implementing pathogenic sequence screening

Database screening involves several legal, scientific, and operational difficulties.

Incomplete databases: Newly identified pathogenic sequences may not immediately appear in reference databases.

False positive results: Similarity between sequences does not necessarily establish that a sequence is dangerous.

Scientific uncertainty: Genetic functions may not be fully understood.

International differences: Countries may apply different screening and reporting standards.

Privacy concerns: Human genetic datasets may contain identifiable personal information.

Commercial confidentiality: Screening procedures may involve proprietary information belonging to research institutions or companies.

Regulatory gaps: Existing laws do not establish one universal screening standard for every biological sequence database.

Safeguards and regulatory recommendations

India should encourage consistent institutional screening policies supported by recognised scientific standards and qualified biosafety professionals. Universities, research laboratories, and DNA synthesis organisations should establish documented review procedures and clear responsibilities for handling potentially concerning results.

Screening systems should be periodically evaluated for accuracy, scientific limitations, and security vulnerabilities. Human genetic information should receive appropriate privacy protection, while access to sensitive biological information should follow applicable legal and ethical requirements.

International cooperation is also important because biological research and genetic information frequently cross national boundaries.

Conclusion

Database screening for pathogenic sequences is an important component of modern biotechnology governance and biosecurity. It supports responsible scientific research, public health protection, and the identification of potentially harmful biological risks. Indian environmental, biotechnology, privacy, and cybersecurity laws provide a foundation for regulating relevant activities, although specific regulatory standards for sequence screening require further development. A balanced framework involving scientific validation, institutional accountability, privacy protection, and international cooperation can strengthen both research freedom and biological safety.